Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Science 37 (NASDAQ:SNCE) and Catalent have announced a strategic partnership to revolutionize clinical trial accessibility through direct-to-patient delivery of investigational medicinal products (IMPs). The collaboration has demonstrated significant success across 17 studies, enrolling 1,700 patients with an average of 26% of total study populations through a single Direct-to-Patient Site.
The partnership has already facilitated over 6,400 shipments to study participants, achieving an enrollment rate of 9 patients per month - equivalent to more than 15 traditional brick-and-mortar locations. This integrated solution offers sponsors a streamlined approach with a single contract and budget, while expanding access to underserved populations.
Science 37 (NASDAQ:SNCE) e Catalent hanno siglato una partnership strategica per rivoluzionare l'accesso agli studi clinici mediante la consegna diretta al paziente di prodotti medicinali sperimentali (IMP). La collaborazione ha già ottenuto risultati rilevanti in 17 studi, arruolando 1.700 pazienti con una media del 26% della popolazione totale dello studio gestita tramite un unico Direct-to-Patient Site.
Il partenariato ha effettuato oltre 6.400 spedizioni ai partecipanti, mantenendo un tasso di arruolamento di 9 pazienti al mese — equivalente a oltre 15 sedi tradizionali. Questa soluzione integrata offre agli sponsor un percorso semplificato con un unico contratto e budget, ampliando al contempo l'accesso a popolazioni svantaggiate.
Science 37 (NASDAQ:SNCE) y Catalent han anunciado una alianza estratégica para transformar el acceso a los ensayos clínicos mediante la entrega directa al paciente de productos medicinales en investigación (IMP). La colaboración ha mostrado un éxito notable en 17 estudios, reclutando a 1.700 pacientes con un promedio del 26% de la población total del estudio a través de un único Direct-to-Patient Site.
La asociación ya ha gestionado más de 6.400 envíos a participantes, alcanzando una tasa de reclutamiento de 9 pacientes por mes, equivalente a más de 15 centros presenciales tradicionales. Esta solución integrada ofrece a los patrocinadores un enfoque simplificado con un solo contrato y presupuesto, y amplía el acceso a poblaciones desatendidas.
Science 37 (NASDAQ:SNCE)와 Catalent이 임상시험 접근성을 혁신하기 위해 임상시험 약물(IMP)을 환자에게 직접 배송하는 전략적 파트너십을 발표했습니다. 이 협력은 17개 연구에서 성공을 거두어 1,700명의 환자를 등록했으며, 단일 Direct-to-Patient 사이트를 통해 전체 연구 모집단의 평균 26%를 차지했습니다.
이 파트너십은 이미 참가자에게 6,400건 이상의 배송을 수행했으며, 월평균 9명의 등록 속도를 기록해 전통적인 오프라인 기관 15곳 이상과 맞먹는 성과를 보였습니다. 이 통합 솔루션은 스폰서에게 단일 계약과 예산으로 간소화된 접근을 제공하며, 소외된 인구의 접근성도 확대합니다.
Science 37 (NASDAQ:SNCE) et Catalent ont annoncé un partenariat stratégique visant à transformer l'accès aux essais cliniques par la livraison directe aux patients de médicaments en investigation (IMP). La collaboration a déjà porté ses fruits dans 17 études, recrutant 1 700 patients avec en moyenne 26% de la population totale de l'étude via un seul site Direct-to-Patient.
Le partenariat a réalisé plus de 6 400 expéditions aux participants, atteignant un taux de recrutement de 9 patients par mois, soit l'équivalent de plus de 15 sites traditionnels. Cette solution intégrée offre aux commanditaires une approche simplifiée avec un contrat et un budget uniques, tout en élargissant l'accès aux populations mal desservies.
Science 37 (NASDAQ:SNCE) und Catalent haben eine strategische Partnerschaft angekündigt, um den Zugang zu klinischen Studien durch Direktlieferungen von Prüfpräparaten (IMP) an Patient:innen zu revolutionieren. Die Zusammenarbeit erzielte bereits deutliche Erfolge in 17 Studien und rekrutierte 1.700 Patient:innen, wobei im Mittel 26% der Studienpopulation über eine einzige Direct-to-Patient-Stelle eingeschlossen wurden.
Die Partnerschaft hat mehr als 6.400 Sendungen an Studienteilnehmende durchgeführt und erreicht eine Rekrutierungsrate von 9 Patient:innen pro Monat — das entspricht mehr als 15 herkömmlichen Standorten. Diese integrierte Lösung bietet Sponsor:innen einen schlanken Ablauf mit einem einzigen Vertrag und Budget und erweitert gleichzeitig den Zugang für unterversorgte Bevölkerungsgruppen.
- Successfully enrolled 1,700 patients across 17 studies through direct-to-patient model
- Achieved 26% average enrollment of total study population through a single Direct-to-Patient Site
- Enrollment rate equivalent to more than 15 brick-and-mortar locations
- Completed over 6,400 successful shipments to study participants
- Streamlined operations through single contract and budget model
- None.
Insights
Science 37's partnership with Catalent enhances clinical trial accessibility, accelerating enrollment and boosting geographic reach with impressive early results.
This partnership between Science 37 and Catalent represents a significant operational advancement in decentralized clinical trials. The collaboration directly addresses one of the most challenging aspects of at-home clinical research—the secure and timely delivery of investigational medicinal products to participants' homes across diverse locations.
The preliminary data from this partnership shows compelling operational metrics: across 17 studies, they've enrolled nearly 1,700 patients, with each Direct-to-Patient Site enrolling an average of 26% of the total study population. The enrollment rate of 9 patients per month is particularly notable, as it's equivalent to the output of over 15 traditional research locations. With 6,400+ shipments already delivered, the scale of implementation is substantial.
This model creates value through several mechanisms: it expands the geographic reach of clinical trials, potentially increases diversity in study populations, accelerates enrollment timelines, and streamlines operations under a unified contract structure. For pharmaceutical sponsors, this translates to potential cost efficiencies and faster time-to-market for new treatments.
The real innovation here is the operational integration—creating what amounts to a virtual clinical trial site with the logistical capabilities to handle sensitive medical products. By removing geographic barriers to participation, this approach may help address the persistent industry challenge of slow enrollment and limited diversity in clinical research populations.
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research.
Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by providing reliable, efficient shipping and logistics services for study medications, ensuring rapid and secure delivery of IMPs across geographies and enabling patients to participate in clinical research from the comfort of their homes, regardless of their location.
“Catalent’s expertise in direct-to-patient logistics is a key enabler of our mission to expand access to clinical trials,” said Tyler Van Horn, CEO at Science 37. “By removing geographic barriers, we’re not only reaching more diverse patient populations, we’re also driving faster enrollment and generating high-quality data that helps bring treatments to market sooner.”
Science 37 and Catalent have partnered to refine the IMP supply chain for at-home trial participation and visit execution. Across 17 studies, Catalent and Science 37's partnership enrolled nearly 1,700 patients by bringing clinical trials directly into the home, enrolling an average
This integrated solution offers sponsors an end-to-end clinical trial site under a single contract and budget, streamlining operations, improving enrollment speed and retention rates, and expanding access to underserved and geographically dispersed populations.
“Our partnership with Science 37 transforms the clinical trial experience, bringing research directly to participants while preserving the rigor and efficiency on which sponsors rely,” said Ricky Hopson, President, Clinical and Specialty Services, and Chief of Staff at Catalent. “Together, we’re advancing a more inclusive and patient-centered future for clinical research, without compromising precision or quality.”
To learn more about how Science 37 and Catalent are transforming clinical research, visit www.science37.com and www.catalent.com.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
For more information, visit www.catalent.com.
About Science 37
Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.
To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.
Media Inquiries
Science 37
pr@science37.com
FAQ
What is the partnership between Science 37 (SNCE) and Catalent?
How many patients has the Science 37-Catalent partnership enrolled?
What is the enrollment rate achieved by Science 37's Direct-to-Patient model?
How many shipments has the Science 37-Catalent partnership delivered?
What are the benefits of Science 37's Direct-to-Patient Clinical Trial Site model?
